Chris Peritore-Galve, PhD

Assistant Professor at The Ohio State University | Professional 🦠and 💩 aficionado | Non-professional 🪴🐶🐦 enthusiast | 🇲🇽🇺🇸

[Chris Peritore-Galve, PhD @Peritorus_Rex]

Thrilled to share our new study from the @BordenLacy Lab in collaboration with @AstraZenecaUS, "The monoclonal antibody AZD5148 confers broad protection against TcdB-diverse Clostridioides difficile strains in mice” now out in PLoS Pathogens!
https://t.co/ErOqV4wmyw

[Chris Peritore-Galve, PhD @Peritorus_Rex]

The Peritore Lab officially opens its doors in 2026!

I am seeking an organized, motivated technician to join our team focused on host-pathogen interaction research. For details on current research, check out: https://t.co/8BNlpkN396

Job listing: https://t.co/vU9j0vwne4

[Chris Peritore-Galve, PhD @Peritorus_Rex]

20/20 This was a fun and important study, and it was a pleasure to collaborate between the @BordenLacy Lab and our brilliant colleagues at @AstraZenecaUS !
@RubenCanoRdz @SLKordus @ReeceKnippel & everyone else I couldn't find/tag

[Chris Peritore-Galve, PhD @Peritorus_Rex]

Thrilled to share our new study from the @BordenLacy Lab in collaboration with @AstraZenecaUS, "The monoclonal antibody AZD5148 confers broad protection against TcdB-diverse Clostridioides difficile strains in mice” now out in PLoS Pathogens!
https://t.co/ErOqV4wmyw

[Chris Peritore-Galve, PhD @Peritorus_Rex]

19/20 AZD5148 is currently in Phase I clinical trials (NCT06469151), and we are hopeful that this monoclonal antibody will help C. difficile patients in the future.